Elevance Health Inc.(ELV)
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest News & Analysis
Institutional Validators Affirm Elevance Recovery Thesis Through Q3 Portfolio Builds
Major value investors Seth Klarman and Ruane Cunniff doubled and increased their ELV stakes in Q3, signalling conviction in the 2026-2027 turnaround thesis.
Elevance's Earnings Beat Masks a Troubling Medicaid Hangover
Strong Q3 results obscured by guidance warning that elevated Medicaid costs will persist through 2026, extending the industry's profitability trough.
Elevance Health Acquisition of Granular Insurance: Expanding Employer Solutions
Elevance Health focuses on strategic acquisitions and financial performance amidst market shifts. Key developments and competitive challenges shape investment decisions.
Elevance Health's Employer Insurance Push: Granular Acquisition Analyzed
Elevance Health focuses on employer insurance expansion through strategic acquisitions and addresses Medicaid attrition amid rising healthcare costs.
Elevance Health's Bold Move: Expanding Employer Insurance with Granular Acquisition
Elevance Health (ELV) is strategically expanding its employer insurance business through key acquisitions, strong Q4 earnings, and investments in technology.
Elevance Health (ELV): Strategic Growth, Dividend Performance, and Market Analysis
Elevance Health (ELV) demonstrates a positive market trend driven by strong Q4 earnings and strategic acquisitions. Investors should monitor key financial metrics.
Elevance Health (ELV): Strategic Growth Amidst Healthcare Industry Shifts
Elevance Health (ELV) navigates rising costs, Medicaid changes, and strategic acquisitions. Health-tech investments and dividend strategies aim to drive investor value.
Elevance Health: Navigating Regulatory Challenges and Market Volatility
Elevance Health (ELV) navigates regulatory scrutiny, CarelonRx integration, and market volatility. Strategic acquisitions and dividend strategy are key. Analysis inside.
Elevance Health (ELV): Analyzing Stock Performance, Growth Strategy, and Market Challenges
Analysis of Elevance Health (ELV): Stock performance, growth strategies, market challenges, and the impact of rising medical costs on its future prospects.
Elevance Health (ELV): Strategic Growth, Market Impact, and Future Outlook
Analysis of Elevance Health (ELV): Q4 2024 performance, Medicare/Medicaid policy impacts, Granular Insurance acquisition, AI strategies, stock performance, and growth projections.
Elevance Health (ELV) Q1 2025 Earnings Preview: Key Factors
A comprehensive analysis of Elevance Health's Q1 2025 earnings preview, exploring key factors, analyst expectations, and strategic outlook in the evolving healthcare landscape.
Elevance Health (ELV): Medicare Advantage, Earnings, and Growth
Analysis of Elevance Health (ELV): Medicare Advantage boost, Q1 2025 earnings outlook, strategic investments, membership growth, and policy impacts.
Elevance Health (ELV): Unpacking Q1 Expectations and the 2026 Medicare Advantage Tailwind
Elevance Health (ELV) faces cash flow pressures but anticipates Q1 2025 profit above estimates, bolstered by favorable 2026 Medicare Advantage rates.
Elevance Health (ELV) Navigates Legal Headwinds Amidst Solid Financials
Elevance Health faces securities lawsuits over Medicaid disclosures, impacting its stock despite solid financials and growth projections.
Elevance Health (ELV) Navigates Securities Fraud Lawsuits
Elevance Health Inc. faces new securities fraud lawsuits in June 2025 over alleged Medicaid misrepresentations, impacting its stock and highlighting industry legal risks.
Elevance Health (ELV) Lawsuits: Investor Implications & Market Impact
Elevance Health faces significant legal challenges from securities lawsuits, impacting its stock performance and future earnings. Investors eye the July 11, 2025 deadline.
Elevance Health (ELV): Legal Battles & Strategic Shifts in 2025
Elevance Health faces securities lawsuits, policy changes, and inflation. Explore how these factors impact ELV's financials and strategic direction.
Elevance Health Faces Securities Fraud Lawsuit Amidst Shifting Financials
Elevance Health (ELV) is embroiled in a securities fraud class action lawsuit concerning its Medicare Advantage plans, prompting investor scrutiny.
Elevance Health (ELV): Legal Challenges & Financial Resilience Analysis
Elevance Health (ELV) faces a class action lawsuit over alleged securities fraud, tied to Medicaid redeterminations. This analysis delves into financial impacts, market reactions, and strategic implications for investors.
Elevance Health Inc. (ELV) Latest Developments: Legal Challenges and Financial Analysis
Elevance Health faces a pivotal securities fraud lawsuit amid solid financials and evolving Medicaid risks, shaping investor outlook and strategic positioning.
Elevance Health Inc. (ELV) Faces Securities Fraud Lawsuit Impacting Stock and Investor Sentiment
Elevance Health Inc. stock plunges -10.8% amid securities fraud allegations tied to Medicaid redetermination cost disclosures, raising investor concerns and legal risks.
Elevance Health Inc. (ELV) Latest Developments: Class Action Lawsuit and Financial Insights
Elevance Health faces a class action lawsuit alleging securities fraud tied to Medicaid redeterminations, impacting investor sentiment and stock performance.
Elevance Health Inc. Update: Securities Litigation Impact and Financial Insights - Monexa AI
Elevance Health faces securities litigation over Medicaid redeterminations amid solid financials. Explore detailed analysis of legal risks, earnings, and strategic outlook.
Elevance Health Inc. (ELV) Legal Challenges and Financial Performance Update - Monexa AI
Elevance Health faces a significant securities fraud lawsuit linked to Medicaid redeterminations, affecting stock performance and investor outlook.
Elevance Health Inc. (ELV) Faces Securities Fraud Lawsuit Amid Medicaid Cost Scrutiny and Financial Volatility
Elevance Health Inc. (ELV) confronts a securities fraud lawsuit over Medicaid cost trends, impacting stock performance and investor confidence amid regulatory probes.
Elevance Health Inc. Q2 2025 Analysis: Navigating Litigation and Healthcare Cost Pressures
Elevance Health faces Q2 2025 earnings under scrutiny amid rising healthcare costs and securities fraud allegations impacting valuation and sector outlook.
Elevance Health Inc. Q2 Earnings & Securities Fraud Lawsuit Impact Analysis - Monexa AI
Elevance Health faces securities fraud allegations amid Q2 earnings, with Medicaid redeterminations impacting costs and investor confidence in the health insurance sector.
Elevance Health Inc. Q2 2025 Earnings Analysis: Rising Medical Costs and Strategic Response
Elevance Health faces rising medical costs impacting Q2 2025 earnings and full-year guidance. Explore financials, legal risks, and strategic initiatives shaping its outlook.
Elevance Health (ELV) Faces Lawsuits: Financials and Market Impact
Elevance Health faces securities lawsuits over Medicaid redeterminations' impact, while navigating regulatory changes and analyzing financial performance.
Elevance Health Inc. Q2 2025 Earnings Update: Navigating Rising Medicaid Costs and Legal Challenges
Elevance Health's Q2 2025 earnings reveal rising Medicaid costs, securities lawsuits, and strategic moves in Carelon Services amid investor uncertainty.
Elevance Health Inc. Analysis: CEO Insider Buy Amid Q2 Earnings Challenges and Strategic Growth
Explore Elevance Health's CEO $2.4M stock purchase amid Q2 earnings pressures, rising Medicaid/ACA costs, and strategic digital health growth.
Elevance Health Inc. Q2 2025 Earnings Miss and Strategic Shifts Amid Medical Cost Pressures
Elevance Health Q2 2025 earnings missed estimates due to rising medical costs, prompting guidance cuts. Carelon segment growth and CEO stock buy signal strategic confidence.
Elevance Health Inc. (ELV) Q2 2025 Analysis: Earnings Miss, Legal Challenges, and Strategic Growth
Elevance Health faces Q2 earnings miss due to rising ACA and Medicaid costs, legal risks, and strategic investments in Carelon shaping its future.
Elevance Health: Earnings Pressure, Cash Flow & Carelon Growth
Elevance cut 2025 assumptions after ACA/Medicaid cost shocks and mounting litigation; FY2024 net income **$5.98B**, free cash flow **$4.55B**, net debt **$22.94B**.
Elevance Health (ELV): Margin Shock, Carelon Growth, and the $375M Star-Rating Fallout
Elevance trims 2025 adjusted EPS to ~**$30.00** as Q2 benefit expense ratio jumps to **88.9%**; Carelon growth offsets but does not yet neutralize margin risk.
Elevance Health (ELV): $375M Star-Rating Hit, Margin Pressure and the Case for Execution
Elevance disclosed an approximately $375.0M revenue adjustment tied to a Medicare Advantage star-rating change that will pressure near-term margins and free cash flow.
Elevance Health (ELV): Earnings Resilience Meets Margin Pressure
Elevance reported **$176.81B** revenue in FY2024 with flat net income and rising net debt; MA star-rating setbacks and medical-cost inflation are the key earnings risks.
Elevance Health (ELV) Faces Securities Lawsuits: Financial Impact Analysis
Elevance Health faces securities lawsuits in 2025, raising questions about financial disclosures amid stable fundamentals and strategic shifts.
Elevance Health (ELV): Star-Ratings Ruling, Carelon Growth and the Margin Question
Elevance faces a tangible $375M-plus hit from a star-ratings ruling even as Carelon drives double‑digit service growth; free cash flow and medical-cost trends now determine execution risk.
Elevance Health Inc.: Carelon Growth Masks Margin Squeeze and Legal Overhang
Elevance cut 2025 adjusted EPS to about $30 while Carelon revenue surged ~+36.00% YoY to ~$18.1B; margins compressed as benefit expense ratio climbed to ~88.9%.